300601 康泰生物
已收盘 04-24 15:00:00
资讯
新帖
简况
康泰生物:以未分配利润向全体股东每10股派0.35元(含税)现金红利
证券之星 · 04-22
康泰生物:以未分配利润向全体股东每10股派0.35元(含税)现金红利
4月22日康泰生物涨5.99%,疫苗ETF嘉实基金重仓该股
证券之星 · 04-22
4月22日康泰生物涨5.99%,疫苗ETF嘉实基金重仓该股
康泰生物:公司有布局创新治疗产品,目前尚处在前期阶段
证券之星 · 04-21
康泰生物:公司有布局创新治疗产品,目前尚处在前期阶段
康泰生物最新公告:一季度净利润同比增长48.61%
证券之星 · 04-21
康泰生物最新公告:一季度净利润同比增长48.61%
康泰生物:公司没有九价HPV项目的研发
证券之星 · 04-21
康泰生物:公司没有九价HPV项目的研发
康泰生物最新公告:二价肠道病毒灭活疫苗开启Ⅰ期临床试验
证券之星 · 04-17
康泰生物最新公告:二价肠道病毒灭活疫苗开启Ⅰ期临床试验
康泰生物最新公告:吸附无细胞百白破联合疫苗获临床试验批准
证券之星 · 04-08
康泰生物最新公告:吸附无细胞百白破联合疫苗获临床试验批准
康泰生物(300601)披露2026年第一季度可转换公司债券转股情况公告,4月3日股价下跌2.95%
证券之星 · 04-03
康泰生物(300601)披露2026年第一季度可转换公司债券转股情况公告,4月3日股价下跌2.95%
康泰生物最新公告:全资子公司吸附破伤风疫苗获药品注册证书
证券之星 · 04-03
康泰生物最新公告:全资子公司吸附破伤风疫苗获药品注册证书
康泰生物(300601)披露持股5%以上股东一致行动人内部股份转让完成公告,3月26日股价下跌1.1%
证券之星 · 03-26
康泰生物(300601)披露持股5%以上股东一致行动人内部股份转让完成公告,3月26日股价下跌1.1%
3月24日康泰生物现7765.74万元大宗交易
证券之星 · 03-24
3月24日康泰生物现7765.74万元大宗交易
康泰生物(300601)披露持股5%以上股东一致行动人之间内部转让股份触及1%整数倍的提示性公告,3月20日股价下跌0.49%
证券之星 · 03-20
康泰生物(300601)披露持股5%以上股东一致行动人之间内部转让股份触及1%整数倍的提示性公告,3月20日股价下跌0.49%
康泰生物:预计2025年全年海外业务收入达9,883.53万元,同比增长859.40%
证券之星 · 03-20
康泰生物:预计2025年全年海外业务收入达9,883.53万元,同比增长859.40%
康泰生物最新公告:四价流感病毒裂解疫苗获药品注册证书
证券之星 · 03-20
康泰生物最新公告:四价流感病毒裂解疫苗获药品注册证书
3月19日康泰生物发生6笔大宗交易 成交金额1.2亿元
证券之星 · 03-19
3月19日康泰生物发生6笔大宗交易 成交金额1.2亿元
康泰生物(300601)披露持股5%以上股东一致行动人内部股份转让公告,3月17日股价上涨0.35%
证券之星 · 03-17
康泰生物(300601)披露持股5%以上股东一致行动人内部股份转让公告,3月17日股价上涨0.35%
康泰生物公布国际专利申请:“呼吸道合胞病毒融合前F蛋白突变体及其应用”
证券之星 · 03-17
康泰生物公布国际专利申请:“呼吸道合胞病毒融合前F蛋白突变体及其应用”
康泰生物(300601)披露全资子公司为公司提供2亿元担保进展,3月6日股价上涨1.88%
证券之星 · 03-06
康泰生物(300601)披露全资子公司为公司提供2亿元担保进展,3月6日股价上涨1.88%
3月2日康泰生物发布公告,股东减持209.34万股
证券之星 · 03-02
3月2日康泰生物发布公告,股东减持209.34万股
康泰生物(300601)披露关于更换持续督导保荐代表人的公告,2月25日股价上涨1.34%
证券之星 · 02-25
康泰生物(300601)披露关于更换持续督导保荐代表人的公告,2月25日股价上涨1.34%
加载更多
公司概况
公司名称:
深圳康泰生物制品股份有限公司
所属行业:
医药制造业
上市日期:
2017-02-07
主营业务:
深圳康泰生物制品股份有限公司的主营业务是人用疫苗的研发、生产和销售。公司的主要产品是免疫规划疫苗、非免疫规划疫苗。
发行价格:
3.29
{"stockData":{"symbol":"300601","market":"SZ","secType":"STK","nameCN":"康泰生物","latestPrice":14.04,"timestamp":1777014201000,"preClose":14.27,"halted":0,"volume":15364128,"delay":0,"changeRate":-0.0161,"floatShares":900000000,"shares":1117000000,"eps":0.0728,"marketStatus":"已收盘","change":-0.23,"latestTime":"04-24 15:00:00","open":14.27,"high":14.36,"low":14.04,"amount":218000000,"amplitude":0.0224,"askPrice":14.04,"askSize":352,"bidPrice":14.03,"bidSize":743,"shortable":0,"etf":0,"ttmEps":0.0728,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1777253400000},"marketStatusCode":5,"adr":0,"adjPreClose":14.27,"symbolType":"stock","openAndCloseTimeList":[[1776994200000,1777001400000],[1777006800000,1777014000000]],"highLimit":15.7,"lowLimit":12.84,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":1116929755,"isCdr":false,"pbRate":1.74,"roa":"--","peRate":192.857143,"roe":"0.35%","epsLYR":0.06,"committee":0.540088,"marketValue":15682000000,"turnoverRate":0.0171,"status":1,"floatMarketCap":12641000000},"requestUrl":"/m/hq/s/300601","defaultTab":"news","newsList":[{"id":"2629041656","title":"康泰生物:以未分配利润向全体股东每10股派0.35元(含税)现金红利","url":"https://stock-news.laohu8.com/highlight/detail?id=2629041656","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629041656?lang=zh_cn&edition=full","pubTime":"2026-04-22 20:52","pubTimestamp":1776862329,"startTime":"0","endTime":"0","summary":"证券之星消息,康泰生物04月21日在投资者关系平台上答复投资者关心的问题。投资者提问:康泰生物2025年的业绩公告哪天发布?康泰生物回复:您好,公司2025年具体业绩情况及2026年经营计划详见公司于2026年4月21日在巨潮资讯网披露的2025年年度报告相关内容。暂以2026年3月31日公司总股本1,116,929,755股计算,合计拟派发现金分红金额为39,092,541.43元(含税),占2025年度归属于上市公司股东的净利润比例为55.58%,本次分红方案尚需股东会审议批准后方可实施。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042200051458.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300601","BK0239","BK0046","BK0201"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629001543","title":"4月22日康泰生物涨5.99%,疫苗ETF嘉实基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2629001543","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629001543?lang=zh_cn&edition=full","pubTime":"2026-04-22 16:33","pubTimestamp":1776846839,"startTime":"0","endTime":"0","summary":"证券之星消息,4月22日康泰生物涨5.99%,收盘报14.68元,换手率4.8%,成交量43.23万手,成交额6.44亿元。重仓康泰生物的公募基金请见下表:该股最近90天内共有1家机构给出评级,买入评级1家。根据2026基金Q1季报公募基金重仓股数据,重仓该股的公募基金共2家,其中持有数量最多的公募基金为嘉实基金的疫苗ETF嘉实。疫苗ETF嘉实目前规模为2.25亿元,最新净值0.698,较上一交易日下跌1.04%,近一年上涨13.79%。该公募基金现任基金经理为周泉希。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042200037878.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300601","BK0201","BK0239","562860","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629049080","title":"康泰生物:公司有布局创新治疗产品,目前尚处在前期阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2629049080","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629049080?lang=zh_cn&edition=full","pubTime":"2026-04-21 18:42","pubTimestamp":1776768137,"startTime":"0","endTime":"0","summary":"证券之星消息,康泰生物04月21日在投资者关系平台上答复投资者关心的问题。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042100044316.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0201","BK0239","300601"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629087010","title":"康泰生物最新公告:一季度净利润同比增长48.61%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629087010","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629087010?lang=zh_cn&edition=full","pubTime":"2026-04-21 18:20","pubTimestamp":1776766829,"startTime":"0","endTime":"0","summary":"康泰生物(300601.SZ)公告称,2026年第一季度实现营业收入6.31亿元,同比下降2.18%;归属于上市公司股东的净利润为3333.90万元,同比增长48.61%。业绩变动主要系本报告期受研发资本化时点变更影响及研发投入减少、利息收入减少、资产减值损失减少等因素综合影响所致。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042100042364.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300601"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629822840","title":"康泰生物:公司没有九价HPV项目的研发","url":"https://stock-news.laohu8.com/highlight/detail?id=2629822840","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629822840?lang=zh_cn&edition=full","pubTime":"2026-04-21 17:57","pubTimestamp":1776765435,"startTime":"0","endTime":"0","summary":"证券之星消息,康泰生物04月21日在投资者关系平台上答复投资者关心的问题。投资者提问:董秘你好,沃森年报显示2025年全年研发投入3亿多,贵司有多个项目在研需要研发投入,全年总研发投入3亿多九价HPV是停滞了吗?2025年公司全年研发投入6.33亿元,占当年营业收入的23.69%,具体在研产品情况详见公司于2026年4月21日在巨潮资讯网披露的2025年年度报告相关内容。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042100040631.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0201","BK0239","300601"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628227051","title":"康泰生物最新公告:二价肠道病毒灭活疫苗开启Ⅰ期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2628227051","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628227051?lang=zh_cn&edition=full","pubTime":"2026-04-17 18:31","pubTimestamp":1776421882,"startTime":"0","endTime":"0","summary":"康泰生物(300601.SZ)公告称,公司全资子公司北京民海生物科技有限公司研发的二价肠道病毒灭活疫苗(Vero细胞)已完成Ⅰ期临床试验准备工作,正式开启Ⅰ期临床试验,并成功完成首例受试者入组。该疫苗适用于6月龄及以上EV-A71、CV-A16易感者,用于预防手足口病等传染病。目前全球尚无二价肠道病毒灭活疫苗(Vero细胞)获批上市。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041700037526.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300601","BK0201","BK0046","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625454149","title":"康泰生物最新公告:吸附无细胞百白破联合疫苗获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2625454149","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625454149?lang=zh_cn&edition=full","pubTime":"2026-04-08 19:41","pubTimestamp":1775648460,"startTime":"0","endTime":"0","summary":"康泰生物公告称,公司全资子公司北京民海生物科技有限公司研发的吸附无细胞百白破(组分)联合疫苗于近日获得国家药品监督管理局出具的《药物临床试验批准通知书》,同意本品进行临床试验。该疫苗适用于成人、青少年及儿童,用于预防百日咳、白喉、破伤风。目前国内厂家暂无吸附无细胞百白破(组分)联合疫苗的产品获批上市。公司将尽快开展相关临床试验工作。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040800033668.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0201","BK0046","300601","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624141659","title":"康泰生物(300601)披露2026年第一季度可转换公司债券转股情况公告,4月3日股价下跌2.95%","url":"https://stock-news.laohu8.com/highlight/detail?id=2624141659","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624141659?lang=zh_cn&edition=full","pubTime":"2026-04-03 17:39","pubTimestamp":1775209157,"startTime":"0","endTime":"0","summary":"截至2026年4月3日收盘,康泰生物报收于13.81元,较前一交易日下跌2.95%,最新总市值为154.25亿元。该股当日开盘14.12元,最高14.22元,最低13.8元,成交额达1.32亿元,换手率为1.05%。近日,深圳康泰生物制品股份有限公司发布2026年第一季度可转换公司债券转股情况公告。2026年第一季度,共有60张“康泰转2”完成转股,合计转为380股公司股票。截至2026年3月31日,剩余可转债为19,989,850张,票面总金额为1,998,985,000元。公司总股本由1,116,929,375股增至1,116,929,755股。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040300034600.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0201","BK0046","300601","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624943656","title":"康泰生物最新公告:全资子公司吸附破伤风疫苗获药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2624943656","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624943656?lang=zh_cn&edition=full","pubTime":"2026-04-03 17:01","pubTimestamp":1775206912,"startTime":"0","endTime":"0","summary":"康泰生物(300601.SZ)公告称,公司全资子公司北京民海生物科技有限公司研发的吸附破伤风疫苗于今日收到国家药品监督管理局签发的《药品注册证书》。该疫苗主要用于发生创伤机会较多的人群及妊娠期妇女,以预防破伤风。此次获批将进一步丰富公司产品布局,增强核心竞争力。但产品上市时间存在不确定性,敬请投资者注意投资风险。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040300032835.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","159646","300601","BK0201","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622853590","title":"康泰生物(300601)披露持股5%以上股东一致行动人内部股份转让完成公告,3月26日股价下跌1.1%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622853590","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622853590?lang=zh_cn&edition=full","pubTime":"2026-03-26 17:28","pubTimestamp":1774517330,"startTime":"0","endTime":"0","summary":"截至2026年3月26日收盘,康泰生物报收于13.45元,较前一交易日下跌1.1%,最新总市值为150.23亿元。该股当日开盘13.61元,最高13.77元,最低13.39元,成交额达1.09亿元,换手率为0.89%。公告显示,公司于2026年3月24日完成持股5%以上股东袁莉萍及其一致行动人之间的内部股份转让计划。本次转让属于一致行动人之间内部转让,合计持股比例未发生变化,不涉及向市场减持,不影响公司治理结构和控制权。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032600031741.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300601","BK0046","BK0239","BK0201"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621050315","title":"3月24日康泰生物现7765.74万元大宗交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2621050315","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621050315?lang=zh_cn&edition=full","pubTime":"2026-03-24 17:01","pubTimestamp":1774342891,"startTime":"0","endTime":"0","summary":"证券之星消息,3月24日康泰生物发生大宗交易,交易数据如下:近三个月该股共发生25笔大宗交易,合计成交22.8万手,折价成交7笔,溢价成交17笔。该股近期无解禁股上市。截至2026年3月24日收盘,康泰生物(300601)报收于13.66元,上涨3.72%,换手率1.22%,成交量11.02万手,成交额1.48亿元。该股近半年内有股东持股变动,合计净减持209.34万股,股东增减持明细如下表:该股最近90天内共有1家机构给出评级,买入评级1家。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032400028025.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300601","BK0239","BK0046","BK0201"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620732239","title":"康泰生物(300601)披露持股5%以上股东一致行动人之间内部转让股份触及1%整数倍的提示性公告,3月20日股价下跌0.49%","url":"https://stock-news.laohu8.com/highlight/detail?id=2620732239","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620732239?lang=zh_cn&edition=full","pubTime":"2026-03-20 22:34","pubTimestamp":1774017264,"startTime":"0","endTime":"0","summary":"公司于近日披露《关于持股5%以上股东一致行动人之间内部转让股份触及1%整数倍的提示性公告》。本次转让后,博普私募基金产品持股比例由1.79%降至1.09%,华宝万盈私募基金产品持股比例由0.83%升至1.52%。本次股份转让属于一致行动人之间的内部转让,合计持股比例未发生变化,不涉及向市场减持,不影响公司治理结构和控制权。华宝万盈私募基金产品将放弃所持股份的表决权。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032000043821.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0201","BK0046","BK0239","300601"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620780272","title":"康泰生物:预计2025年全年海外业务收入达9,883.53万元,同比增长859.40%","url":"https://stock-news.laohu8.com/highlight/detail?id=2620780272","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620780272?lang=zh_cn&edition=full","pubTime":"2026-03-20 19:12","pubTimestamp":1774005128,"startTime":"0","endTime":"0","summary":"证券之星消息,康泰生物03月20日在投资者关系平台上答复投资者关心的问题。2025 年,公司海外注册工作稳步推进,相关产品相继取得海外 GMP 认证及多国注册批件,进一步完善公司疫苗产品海外市场布局。预计2025年全年海外业务收入达9,883.53万元,同比增长859.40%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032000035391.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300601","BK0046","BK0201","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620782490","title":"康泰生物最新公告:四价流感病毒裂解疫苗获药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2620782490","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620782490?lang=zh_cn&edition=full","pubTime":"2026-03-20 18:10","pubTimestamp":1774001439,"startTime":"0","endTime":"0","summary":"康泰生物(300601.SZ)公告称,公司研发的四价流感病毒裂解疫苗获得国家药监局签发的《药品注册证书》。四价流感病毒裂解疫苗适用于3岁及以上人群,可刺激机体产生抗流感病毒的免疫力,用于预防疫苗相关型别的流感病毒引起的流行性感冒。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032000033781.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","159646","BK0046","BK0201","300601"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620436592","title":"3月19日康泰生物发生6笔大宗交易 成交金额1.2亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2620436592","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620436592?lang=zh_cn&edition=full","pubTime":"2026-03-19 16:59","pubTimestamp":1773910747,"startTime":"0","endTime":"0","summary":"证券之星消息,3月19日康泰生物发生大宗交易,交易数据如下:近三个月该股共发生14笔大宗交易,合计成交17.48万手,折价成交7笔,溢价成交6笔。该股近期无解禁股上市。截至2026年3月19日收盘,康泰生物(300601)报收于14.17元,下跌0.49%,换手率1.39%,成交量12.52万手,成交额1.77亿元。该股近半年内有股东持股变动,合计净减持209.34万股,股东增减持明细如下表:该股最近90天内共有1家机构给出评级,买入评级1家。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031900027023.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0201","300601","BK0046","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620473425","title":"康泰生物(300601)披露持股5%以上股东一致行动人内部股份转让公告,3月17日股价上涨0.35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2620473425","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620473425?lang=zh_cn&edition=full","pubTime":"2026-03-17 22:20","pubTimestamp":1773757233,"startTime":"0","endTime":"0","summary":"公司于近日披露《关于持股5%以上股东一致行动人之间内部转让股份触及1%整数倍的提示性公告》。公告显示,持股5%以上股东袁莉萍的一致行动人博普私募基金产品于2026年3月16日通过大宗交易方式将其持有的公司9,215,000股转让给另一一致行动人华宝万盈私募基金产品。本次转让属于一致行动人之间的内部股份转让,不涉及向市场减持,合计持股比例未发生变化。袁莉萍及其一致行动人合计持股仍为21.12%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031700042002.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300601","BK0201","BK0239","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620975084","title":"康泰生物公布国际专利申请:“呼吸道合胞病毒融合前F蛋白突变体及其应用”","url":"https://stock-news.laohu8.com/highlight/detail?id=2620975084","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620975084?lang=zh_cn&edition=full","pubTime":"2026-03-17 05:52","pubTimestamp":1773697936,"startTime":"0","endTime":"0","summary":"证券之星消息,根据企查查数据显示康泰生物(300601)公布了一项国际专利申请,专利名为“呼吸道合胞病毒融合前F蛋白突变体及其应用”,专利申请号为PCT/CN2025/118795,国际公布日为2026年3月12日。专利详情如下:图片来源:世界知识产权组织(WIPO)今年以来康泰生物已公布的国际专利申请1个。结合公司2025年中报财务数据,2025上半年公司在研发方面投入了2.97亿元,同比增34.85%。数据来源:企查查以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031700004329.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300601","BK0201","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617635403","title":"康泰生物(300601)披露全资子公司为公司提供2亿元担保进展,3月6日股价上涨1.88%","url":"https://stock-news.laohu8.com/highlight/detail?id=2617635403","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617635403?lang=zh_cn&edition=full","pubTime":"2026-03-06 22:29","pubTimestamp":1772807356,"startTime":"0","endTime":"0","summary":"截至2026年3月6日收盘,康泰生物报收于14.08元,较前一交易日上涨1.88%,最新总市值为157.26亿元。近日,康泰生物披露《关于全资子公司为公司提供担保的进展公告》。该担保事项系基于公司2025年4月18日董事会审议通过的授信及互保安排,其中全资子公司为公司提供担保总额不超过100,000万元。截至公告日,公司及子公司对外担保本金余额9,075.16万元,占2024年度经审计净资产的0.94%,无逾期担保及其他担保事项。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030600040351.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0046","BK0201","300601"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616332098","title":"3月2日康泰生物发布公告,股东减持209.34万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2616332098","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616332098?lang=zh_cn&edition=full","pubTime":"2026-03-02 21:01","pubTimestamp":1772456472,"startTime":"0","endTime":"0","summary":"证券之星消息,3月2日康泰生物发布公告《康泰生物:关于控股股东的一致行动人减持期限届满暨实施情况的公告》,其股东杜兴连于2025年12月8日至2026年2月27日间合计减持209.34万股,占公司目前总股本的0.1874%,变动期间该股股价下跌3.77%,截止2月27日收盘报15.05元。股东增减持详情见下表:根据康泰生物2025年三季报公布的十大股东详情如下:以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030200037279.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300601","BK0239","BK0201","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614035961","title":"康泰生物(300601)披露关于更换持续督导保荐代表人的公告,2月25日股价上涨1.34%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614035961","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614035961?lang=zh_cn&edition=full","pubTime":"2026-02-25 22:33","pubTimestamp":1772029997,"startTime":"0","endTime":"0","summary":"截至2026年2月25日收盘,康泰生物报收于15.14元,较前一交易日上涨1.34%,最新总市值为169.1亿元。康泰生物于2026年2月25日发布公告称,因中信建投证券原保荐代表人徐兴文先生工作变动,不再担任公司2021年向不特定对象发行可转换公司债券持续督导保荐代表人。为保证持续督导工作顺利进行,中信建投证券委派贾哲先生自2026年2月25日起接替其职务。公司董事会对徐兴文先生在持续督导期间的贡献表示感谢。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022500038239.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0239","BK0201","300601"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1777146633896,"stockEarnings":[{"period":"1week","weight":-0.0021},{"period":"1month","weight":0.0324},{"period":"3month","weight":-0.1209},{"period":"6month","weight":-0.1496},{"period":"1year","weight":0.0215},{"period":"ytd","weight":-0.0494}],"compareEarnings":[{"period":"1week","weight":0.007},{"period":"1month","weight":0.0377},{"period":"3month","weight":-0.0136},{"period":"6month","weight":0.0328},{"period":"1year","weight":0.2374},{"period":"ytd","weight":0.028}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"深圳康泰生物制品股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"61919人(较上一季度增加1.07%)","perCapita":"14541股","listingDate":"2017-02-07","address":"广东省深圳市南山区粤海街道科技园社区科发路222号康泰集团大厦","registeredCapital":"111692万元","survey":" 深圳康泰生物制品股份有限公司的主营业务是人用疫苗的研发、生产和销售。公司的主要产品是免疫规划疫苗、非免疫规划疫苗。","listedPrice":3.29},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"康泰生物(300601)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供康泰生物(300601)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"康泰生物,300601,康泰生物股票,康泰生物股票老虎,康泰生物股票老虎国际,康泰生物行情,康泰生物股票行情,康泰生物股价,康泰生物股市,康泰生物股票价格,康泰生物股票交易,康泰生物股票购买,康泰生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"康泰生物(300601)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供康泰生物(300601)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}